How low does this go? I understand dilution (which no one likes) and the need for capital, but now we're approaching 20% off recent highs. Grrrr!
While initially disappointed and always hate dilution, I think it is actually not a bad move for Halozyme. If calculated correctly, they are actually buying shares at the predilution price of 13.377. The 12.5 price takes into account the dilution. The fact that they are able to get 100 million dollars of financing for that price is not bad. Obviously financing costs make it slightly less - but it is less than a 10% solution, and it saves the financing rate if they had just borrowed money on a yearly basis. Actually, this is smarter than borrowing right now as it is a limited dilution of shares and I am happy that people were willing to put up 100 million at this price. It also protects them from making a bad deal if they got too close to needing money. I suspect the share price will be back in the 15 range by the time FDA decision in June ready to be announced.
Will fail it's phase 3 trial. This is a shell company that has no future! Get out while you can!!!
This will trade similar to ZIOP after their secondary. Look for $14 by EOD. Good move by the company.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.7 In other words, the correlation coefficient of the other stock
Just started looking into Halo. The 10Q, was a real mess. 100 mil should help get things in order.
CEO is a total MoronShe just kicked the old man in the #$%$.
HALO = FAIL
Timber!!!! You've just been diluted!!! LOLOLOLOLOL!
Next will be failed trial! Get ready long losers! Bwahahahaha! Made mucho money shorting. Ahahahahaha!
Keep in mind...HALO is up 40% from the beginning of the year. Continue to be patient.
Kirk still here, although you don't hear him mentioned much. You know he would like to cash out here so he can fund his other dogs; ziop and xon
"So as further reported, that a high rate of death was observed in the PEGPH20 treatment arm versus the modified FOLFIRINOX lone arm"
This was never reported before to shareholders. This is serious and Helen had no explanation but said it wouldn't affect the PAG trial. That's a bold statement as it certainly could if the FDA get wind that there's a problem with PEG.
Royalties down from last quarter. What are Shire doing with HyQ? Absolutely nothing. And EU Roche sales of SC Mab and Herceptin have peaked already? What a completely uninspiring quarter - yet again. Being a HALO investor is testing our patience.
Get ready for a blazing haircut today!!!
Looks like a good short candi ate now! Weeeeeeeee!
HALO may be a compelling opportunity. I started receiving notifications from awesome-STOCKS the other week and so far they have presented interesting new trade ideas.